Allogenic Stem Cells in Anal Fistulas of Crohn’s Disease: From Promising Premises to Real Life Experience
Inflammatory Bowel Diseases · 2025
DOI: 10.1093/ibd/izae065 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Inflammatory Bowel Diseases, 2025. Verfasst von Charlène Brochard und 7 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology and Physiology Units, University of Rennes 1, Inphy group CIC 1414 CHU-Ponchaillou, 35000 Rennes, France. Hauptthemen laut MEDLINE: Crohn Disease, Rectal Fistula, Stem Cell Transplantation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
Background
Allogenic adipocyte stem cells represent an unprecedented opportunity for regenerative therapy to treat Crohn anal fistulas. Apart from the results of one 8-year-old trial, scientific evidence remains scarce.
Methods
Data from consecutive patients treated with darvadstrocel for Crohn anal fistulas were reviewed at 6 first tertiary reference centers. The judgment criteria combined asymptomatic status plus clinical occlusion of the fistula tract and MRI-confirmed healing of the tract (no inflammation and/or disappearance of the tract). Both clinical and MRI-confirmed healing of the tract defined a deep remission. Clinical remission was defined by an absence of complaint, occlusion of all external openings, and no fistula discharge.
Results
A total of 116 patients were extracted (median follow-up after cell stem injection: 11 [6-14] months). No severe adverse events were reported after surgery except for subsequent anal surgery in 29 (25%) patients. Fifty-one (44%) patients had clinical remission defined by the absence of complaints, the occlusion of all external openings, and the presence of no fistula discharge. Deep remission was observed in 23 (29%) patients. Patients with clinical remission more often received combined therapy (immunosuppressant antitumor necrosis factors) than those with no improvement (31 of 51 [61%] vs 23 of 65 [35%]; P = .007). Regression analysis showed that high fistulas (odds ratio, 3.8 [1.1-12.5]; P = .03) and younger age (<38 years, odds ratio, 2.3 [1.0-58;4]; P = .02) were associated with a better outcome.
Conclusions
Allogeneic stem cell treatment of Crohn’s anal fistulas results in complete remission in less than half of patients, with a significant reintervention rate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Gastroenterology and Physiology Units, University of Rennes 1, Inphy group CIC 1414 CHU-Ponchaillou, 35000 Rennes, France.
- Department of Medicosurgical Proctology Groupe Hospitalier Paris Saint Joseph 185, rue Raymond Losserand, 75014, Paris, France.
- Department of Colorectal Surgery, CHU Lille, France.
- Department of Colorectal Surgery, CHU Amiens, France.
- Proctology Unit Bagatelle Hospital, 33400 Talence, France.
- Proctology, Groupe Hospitalier Diaconesses-Croix Saint-Simon, 125 rue d'Avron, 75020 Paris, France.
ORCID-Profile: Charlène Brochard
Zitieren
APA
Brochard, C., Siproudhis, L., Fathallah, N., Zerbib, P., Sabbagh, C., Bouchard, D., Etienney, I., & Cotte, E. (2025). Allogenic Stem Cells in Anal Fistulas of Crohn’s Disease: From Promising Premises to Real Life Experience. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izae065
Vancouver
Brochard C, Siproudhis L, Fathallah N, Zerbib P, Sabbagh C, Bouchard D, et al. Allogenic Stem Cells in Anal Fistulas of Crohn’s Disease: From Promising Premises to Real Life Experience. Inflammatory Bowel Diseases. 2025. doi:10.1093/ibd/izae065
BibTeX
@article{Brochard2025,
author = {Brochard, Charlène and Siproudhis, Laurent and Fathallah, Nadia and Zerbib, Philippe and Sabbagh, Charles and Bouchard, Dominique and Etienney, Isabelle and Cotte, Eddy},
title = {Allogenic Stem Cells in Anal Fistulas of Crohn’s Disease: From Promising Premises to Real Life Experience},
journal = {Inflammatory Bowel Diseases},
year = {2025},
doi = {10.1093/ibd/izae065}
}
EUVIMED